Tetni-Vax

Manufacturer: AgriPharm

Clostridium chauvoei-septicum-haemolyticum-novyi-tetani-perfringens Types C & D Bacterin-Toxoid

U.s. Vet. Lic. No.

311

Active Ingredient(s)

A formalin-inactivated, alum-precipitated bacterin-toxoid prepared from highly toxigenic cultures and culture filtrates of Clostridium chauvoei, Cl. septicum, Cl. haemolyticum (known elsewhere as Cl. novyi type D), Cl. novyi, Cl. tetani, and Cl. perfringens types C and D. TETNI-VAX^® is an Electroferm^® product produced by an electronically controlled deep culture process.

Tetni-Vax Indications

For the active immunization of healthy sheep and cattle against diseases caused by Clostridium chauvoei, Cl. septicum, Cl. haemolyticum (known elsewhere as Cl. novyi type D), Cl. novyi, Cl. tetani, and Cl. perfringens types C and D.

Although Cl. perfringens type B is not a significant problem in the U.S.A., immunity may be provided against the beta and epsilon toxins elaborated by Cl. perfringens type B. The immunity is derived from the combination of type C (beta) and type D (epsilon) fractions.

Tetni-Vax Dosage And Administration

Shake well. Using aseptic technique, inject 5 mL subcutaneously followed by a 2 mL dose in six (6) weeks. Revaccinate annually with 2 mL prior to periods of extreme risk, or parturition. For Cl. novyi and Cl. haemolyticum, revaccinate every five (5) to six (6) months. Vaccination should be scheduled so that pregnant ewes receive their second vaccination or annual booster two (2) to six (6) weeks before lambing commences in the flock. Lambs should be given their primary course beginning at 10 to 12 weeks of age.

Precaution(s)

Store at 35°-45°F (2°-7°C). Protect from freezing.

Use the entire contents when first opened.

Tetni-Vax Caution(s)

This product has been tested under laboratory conditions and has met all federal standards for safety and ability to immunize normal healthy animals. The level of performance may be affected by conditions of use such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies or impaired immunological competency. These factors should be considered by the user when evaluating product performance or freedom from reactions.

Anaphylactic reactions may occur following use.

Antidote(s)

Epinephrine.

Warning(s)

Do not vaccinate within 21 days before slaughter.

Discussion

The specific toxoids and/or cellular antigens required for optimal disease protection are emphasized in the growth of Electroferm^® cultures. These cultures are highly concentrated and, when divided for the blending of combination vaccines, make possible the production of the low volume dose. Exacting procedures are employed to ensure that each dose of combination vaccine contains an appropriate amount of each component.

All components of each serial of the final product are tested for potency using USDA-accepted laboratory and/or host animal tests.

Trial Data

The protective value of all components of TETNI-VAX^® has been demonstrated through the most critical test procedures available. Vaccinated sheep withstood the challenge of massive doses of virulent live spores of Cl. chauvoei, Cl. septicum, Cl. tetani, Cl. novyi types B and D. Cl. perfringens types C and D, for which no host animal direct-challenge test exists, were evaluated by measuring the amount of antitoxin produced by cattle, sheep and laboratory animals.

TETNI-VAX is a registered trademark of Dealer Distribution of America.

Presentation

10 dose (50 mL) and 50 dose (250 mL) vials.

Nac No.

14571310